Minimum inhibitory concentration distributions for Mycobacterium avium complex—towards evidence-based susceptibility breakpoints | Zendy

Thomas Schön | Zendy; Erja Chryssanthou | Zendy

Open Access

Minimum inhibitory concentration distributions for Mycobacterium avium complex—towards evidence-based susceptibility breakpoints

Author(s) -

Thomas Schön,

Erja Chryssanthou

Publication year - 2017

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.12.027

Subject(s) - breakpoint , minimum inhibitory concentration , mycobacterium avium complex , mycobacterium , microbiology and biotechnology , inhibitory postsynaptic potential , biology , genetics , bacteria , antimicrobial , neuroscience , chromosomal translocation , gene

Patients with clinical infections caused by the Mycobacterium avium complex (MAC) are treated for at least 1 year following sputum conversion with a regimen that suffers from a suboptimal cure rate. The correlation between clinical outcome and drug susceptibility testing breakpoints other than for the macrolides is regarded to be poor. A systematic evaluation of clinical breakpoints for MAC has not been performed so far; thus, the aim of this study was to initiate the process by establishing minimum inhibitory concentration (MIC) distributions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research